Gene regulatory programs driving metabolic maturation ofhuman pluripotent stem cell derived beta-cells
- Institution
- UNIVERSITY OF COLORADO DENVER, CO
- Principal investigator
- Han Zhu
- Funding
- $156K
- Duration
- 2024–2025
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Type 1 diabetes (T1D) is characterized by autoimmune destruction of insulin-producing β-cells in the pancreatic islets. Several theories have been proposed to explain T1D pathogenesis including aberrant immune cell activity as well as increased β-cell sensitivity to inflammatory and metabolic stressors. It has become increasingly apparent that β-cells may not be passive immune cell targets but can contribute to the disease intrinsically. However, it remains unclear whether the risk of developing T1D is already introduced during β-cell formation. Postnatal β-cell maturation may be a T1D relevant β-cell developmental process, not only because it occurs during the peak incidence of T1D diagnosis but also because it determines whether an individual has an adequate functional β-cell pool to cope with environmental stressors. However, the mechanisms underlying human β-cell maturation have been understudied due to the absence of an appropriate human β-cell model. While human pluripotent stem cell (hPSC)-derived β-cells (SC-β-cells) hold immense potential for modeling T1D, current production methods do not permit proper functional maturation, hampering their utility in studying β-cell maturation. One of the hallmark features of mature β-cells is glucose-induced mitochondrial respiration, which is lacking in SC-β-cells. It has been suggested that environmental cues, such as nutrients and circadian rhythm, drive β-cell maturation and establish a mature β-cell state through gene expression regulation and epigenetic modifications. Our objective is to uncover gene regulatory mechanisms that underlie the acquisition of glucose- dependent mitochondrial function in human β-cells and assess the suitability of SC-β-cells as a model for studying β-cell maturation. This work will leverage the genomic and genetic methodologies that we have previously developed for SC-β-cells, including a platform for genome-wide functional perturbation screening, single-cell genomics assays, and a computational tool to infer gene regulatory networks. Expanding on our preliminary studies, we propose to investigate and modify key transcriptional programs governing SC-β-cell mitochondrial activity and induce maturation in vitro (Aim 1). Mechanistically, we plan to investigate the correlation between changes in SC-β-cell function and the epigenome that occurs during the maturation process (Aim 2). It has been established that SC-β-cells exhibit improved function following engraftment into mice. Thus, in the second aim of our study, we will also investigate epigenetic alterations that occur during this in vivo maturation process. We anticipate that our in vitro manipulation of key transcriptional programs will induce similar epigenetic remodeling as observed in vivo. Together, our proposed study will advance the culture of SC-β-cells and demonstrate their utility as a model for investigating human β-cell maturation.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF COLORADO DENVER
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Stanford UniversityNot yet scored
A Targeted Approach to Treat Immunotherapy-Induced Myocarditis with CXCR3 Blockade
Han Zhu · $774K · 2025–2029
- NIH · Stanford UniversityNot yet scored
Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR Phenotyping
Han Zhu · $745K · 2024–2029
- NIH · Stanford UniversityNot yet scored
CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy Myocarditis
Han Zhu · $118K · 2024–2026